Yogita Bahl

Yogita Bahl is a seasoned professional in regulatory CMC and biopharmaceutical development with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Senior Director/Team Lead for RegCMC Cell Therapy at Bristol Myers Squibb since May 2022, Yogita has previously held leadership roles at Daiichi Sankyo, Inc., Novartis, and Merck, contributing expertise in biologics, medical devices, and combination products. Notably, at Amgen Inc, Yogita led a cross-functional team managing drug product aspects for key products with substantial commercial success. Academic credentials include a Ph.D. in Pharmaceutical Sciences from the University of Tennessee-Health Science Center and a Bachelor of Science in Pharmacy from the University of Mumbai.